Xenon Pharmaceuticals Inc (FRA:XP0)

€ 42.4 0.6 (1.44%) Market Cap: 3.16 Bil Enterprise Value: 2.50 Bil PE Ratio: 0 PB Ratio: 4.10 GF Score: 41/100

Q2 2024 Xenon Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2024

€36.8 (-5.15%)

Earnings
Xenon Pharmaceuticals Inc Corporate Update Transcript
Nov 27, 2023
Q3 2023 Xenon Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2023

€29.6 (-3.27%)

Earnings
Xenon Pharmaceuticals Inc XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs Transcript
Sep 19, 2023
Q2 2023 Xenon Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2023

€32.2 (+0.63%)

Earnings
Xenon Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Xenon Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Xenon Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 01, 2023
Xenon Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
Xenon Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Xenon Pharmaceuticals Inc Earnings Call Transcript
May 09, 2023

€38.6 (+0.52%)

Earnings
Xenon Pharmaceuticals Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
Xenon Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2023
Q4 2022 Xenon Pharmaceuticals Inc Earnings Call Transcript
Mar 01, 2023

€37.2 (+1.09%)

Earnings
Xenon Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Xenon Pharmaceuticals Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022
Q3 2022 Xenon Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2022

€34.6 (-3.35%)

Earnings
Q2 2022 Xenon Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2022

€38.8 (+2.65%)

Earnings
Xenon Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 01, 2022
Q1 2022 Xenon Pharmaceuticals Inc Earnings Call Transcript
May 10, 2022

€24.2 (-5.47%)

Earnings
Xenon Pharmaceuticals Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 03, 2022
Xenon Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Xenon Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 29, 2022
Q4 2021 Xenon Pharmaceuticals Inc Earnings Call Transcript
Mar 01, 2022

€28.8 (+5.88%)

Earnings
Xenon Pharmaceuticals Inc X-TOLE Results Update AES 2021 Call Transcript
Dec 03, 2021
Q3 2021 Xenon Pharmaceuticals Inc Earnings Call Transcript
Nov 10, 2021

€30.4 (+4.83%)

Earnings
Xenon Pharmaceuticals Inc Positive Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101 Call Transcript
Oct 04, 2021
Q2 2021 Xenon Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2021

€13.8 (-1.43%)

Earnings
Xenon Pharmaceuticals Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Xenon Pharmaceuticals Inc Discussion of XEN1101 and the Focal Epilepsy Landscape Transcript
Jul 12, 2021
Q1 2021 Xenon Pharmaceuticals Inc Earnings Call Transcript
May 11, 2021

€14.5 (+0.69%)

Earnings
Full Year 2020 Xenon Pharmaceuticals Inc Earnings Call Transcript
Mar 01, 2021

€15.4 (+1.99%)

Earnings
Q3 2020 Xenon Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

€9.45 (+2.72%)

Earnings
Q2 2020 Xenon Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2020

€9.5 (+3.26%)

Earnings
Xenon Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 01, 2020
Q1 2020 Xenon Pharmaceuticals Inc Earnings Call Transcript
May 21, 2020

€12.8 (-1.54%)

Earnings
Q4 2019 Xenon Pharmaceuticals Inc Earnings Call Transcript
Mar 09, 2020

€12.2 (-3.94%)

Earnings
Xenon Pharmaceuticals Inc. - Special Call Transcript
Dec 02, 2019
Q3 2019 Xenon Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2019

€7.95 (+3.92%)

Earnings
Q2 2019 Xenon Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2019

€7.75 (-4.79%)

Earnings
Q1 2019 Xenon Pharmaceuticals Inc Earnings Call Transcript
May 07, 2019

€8.45 (+4.84%)

Earnings
Full Year 2018 Xenon Pharmaceuticals Inc Earnings Call Transcript
Mar 06, 2019

€7.5 (-1.57%)

Earnings

Q4 2022 Xenon Pharmaceuticals Inc Earnings Call Transcript

Mar 01, 2023 / 09:30PM GMT

Release Date Price: €37.2 (+1.09%)

Transcript 10-K8-K

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call. I would now like to turn the call over to Sherry Aulin, CFO. Please go ahead.

Sherry Aulin

Xenon Pharmaceuticals Inc. - CFO

Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's Fourth Quarter and Full Year 2022 financial and operating results. Joining me are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Dr. Chris Von Seggern, Xenon's Chief Commercial Officer.

Ian will open today's call with a summary of progress across our pipeline. Chris Kenny will provide an overview of our XEN1101 Phase III epilepsy program as well as a brief summary of additional supporting X-TOLE data we released in December, and I will summarize our financial results, progress within our partnered programs and our anticipated company milestone events. Chris Von Seggern will be available during our Q&A session to address questions about our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.